Обмінні процеси жирних кислот загальних ліпідів у рідкому вмісті рубця та продуктивні ознаки корів за наявності в їх раціоні кавового шламу

The biochemical mechanisms of action available in the diet in the summer of coffee sludge on metabolic processes in the body and productive performance of cows are poorly understood. The purpose of the study was to metabolism of nitrogenous compounds in liquid capacious rumen, milk production and composition of milk cows in the presence of the coffee slurry in the diet in the summer. Higher levels of fat obtained by the addition to the diet of cows coffee sludge. Cows fed feed consisting of coffee slurry in an amount of 8 and 16%. Established that the average daily feed of cows in the body, which together with the young grasses and legumes and forage fed coffee sludge reported in 4.2 and 11.2% more neutral detergent and 4.5 and 12.2% acid detergent fiber. Feeding cows coffee sludge results in reduction of nitrogen ammonia and amino nitrogen in their liquid roomy scar regardless of time relative to the start of feeding. Thus, the amount of protein nitrogen in the rumen fluid of cows increased research at the 10th hour from the start of feeding, and general – to 7–10th. As a result of feeding the young grass, fodder and coffee sludge cows increased average daily milk yield. At the same time research in the milk of cows increased protein, fat and lactose. The most pronounced effect on the metabolism of nitrogenous compounds in the rumen of cows and productive performance makes extra feeding cows with young grasses and legumes and forage, coffee slurry in an amount of 16% by weight of feed.Біохімічні механізми впливу наявного в раціоні у літній період кавового шламу на обмінні процеси в організмі та продуктивні показники корів є маловивченими. Мета роботи полягала в дослідженні обмінних процесів азотовмісних сполук у рідкому вмісті рубця, молочної продуктивності й складу молока корів за наявності кавового шламу в раціоні у літній період. Вищий рівень клітковини одержали за рахунок додавання до раціону корів кавового шламу. Коровам у складі комбікорму згодовували кавовий шлам у кількості 8 і 16%. Встановлено, що середньодобово з кормами в організм корів, яким разом з молодою злаково-бобовою травою та комбікормом згодовували кавовий шлам, надходило на 4,2 і 11,2% більше нейтральнодетергентної і 4,5 і 12,2% кислотнодетергентної  клітковини. Згодовування коровам кавового шламу приводить до зменшення концентрації азоту аміаку та амінного азоту в їх рідкому вмісті рубця незалежно від часу стосовно початку годівлі. При цьому кількість білкового азоту в рубцевій рідині дослідних корів збільшувалася на 10-й годині від початку годівлі, а загального – на 7–10-й. У результаті згодовування молодої трави, комбікорму та кавового шламу в корів підвищуються середньодобові надої молока. Одночасно в молоці дослідних корів збільшується вміст білка, жиру та лактози. Найбільш виражений вплив на обмінні процеси азотовмісних сполук у рубці та продуктивні показники корів справляє додаткове згодовування коровам разом з молодою злаково-бобовою травою та комбікормом кавового шламу в кількості 16% від маси комбікорму

Suppressor Analysis Reveals a Role for SecY in the SecA2-Dependent Protein Export Pathway of Mycobacteria

All bacteria use the conserved Sec pathway to transport proteins across the cytoplasmic membrane, with the SecA ATPase playing a central role in the process. Mycobacteria are part of a small group of bacteria that have two SecA proteins: the canonical SecA (SecA1) and a second, specialized SecA (SecA2). The SecA2-dependent pathway exports a small subset of proteins and is required for Mycobacterium tuberculosis virulence. The mechanism by which SecA2 drives export of proteins across the cytoplasmic membrane remains poorly understood. Here we performed suppressor analysis on a dominant negative secA2 mutant (secA2 K129R) of the model mycobacterium Mycobacterium smegmatis to better understand the pathway used by SecA2 to export proteins. Two extragenic suppressor mutations were identified as mapping to the promoter region of secY, which encodes the central component of the canonical Sec export channel. These suppressor mutations increased secY expression, and this effect was sufficient to alleviate the secA2 K129R phenotype. We also discovered that the level of SecY protein was greatly diminished in the secA2 K129R mutant, but at least partially restored in the suppressors. Furthermore, the level of SecY in a suppressor strongly correlated with the degree of suppression. Our findings reveal a detrimental effect of SecA2 K129R on SecY, arguing for an integrated system in which SecA2 works with SecY and the canonical Sec translocase to export proteins

СУЧАСНІ ПОГЛЯДИ НА ДІАГНОСТИКУ ТА ПРИНЦИПИ ЛІКУВАННЯ ПАПІЛОМОВІРУСНОЇ ІНФЕКЦІЇ У ЖІНОК

У статті викладено сучасні погляди на діагностику та лікування папіломовірусної інфекції у жінок. Завдяки сучасним діагностичним програмам, а саме молекулярно-біологічній діагностиці та цитологічному дослідженню встановлено, що у 90 % жінок з гострокінцевими кондиломами виявляють ВПЛ типу 6 та 11, а у 20 % жінок рак шийки матки виникає у зв’язку із зараженням ВПЛ типу 16 та 18. Перспективним методом лікування є поєднання загальної та місцевої медикаментозної терапії з локальним хірургічним видаленням кондилом

Differences of two antihypertensive combinations influence on hemodynamic, metabolic features and subfractional status of blood serum in elderly patients with comorbid cardiac pathology

Изучались эффективность и безопасность двух антигипертензивных комбинаций у пожилых пациентов с артериальной гипертензией ІІ и ІІІ стадии в сочетании с ишемической болезнью сердца при влиянии на гемодинамику, метаболический и субфракционный состав. В четырех исследуемых группах выявлены и охарактеризованы клинико-лабораторные и ЛКС-метрические показатели как до начала фармакотерапии, так и в ее динамике. Проведена сравнительная характеристика полученных результатов между группами наблюдения, оценен фармакологический профиль двух использованных комбинаций антигипертензивных препаратов.Choice of combined therapy for treatment of arterial hypertension (AH) associated with coronary artery disease (CAD) is not easy because of pharmacotherapy (PT) peculiarities in the elder age. Low efficacy of PT requires new informative methods for evaluation of homeostatic alterations and assessment of influence of treatment on metabolic processes. The object of our investigation was to reveal efficacy and safety of two antihypertensive combinations during their influence on hemodynamic, metabolic and subfractional status in elderly patients with PH II, III stage combined with CAD. For this purpose 80 patients were examined and treated according to medical standarts in the University Clinic of the Odessa National Medical University

МОЛЕКУЛЯРНОЕ МАРКИРОВАНИЕ ОБРАЗЦОВ ГОРОХА ОВОЩНОГО

The paper presents the results of research on the presence in genomes of pea hybrid materials of the DNA regions complementary to the primers that are associated with the biochemical characteristics and resistance to powdery mildew.В работе представлены результаты исследований гибридного материала гороха овощного на наличие в их геномах участков ДНК, комплементарных ряду праймеров, связанных с биохимическими характеристиками и устойчивостью к настоящей муч нистой росе

Geographical variations in the benefit of applying a prioritization system for cataract surgery in different regions of Spain

<p>Abstract</p> <p>Background</p> <p>In Spain, there are substantial variations in the utilization of health resources among regions. Because the need for surgery differs in patients with appropriate surgical indication, introducing a prioritization system might be beneficial. Our objective was to assess geographical variations in the impact of applying a prioritization system in patients on the waiting list for cataract surgery in different regions of Spain by using a discrete-event simulation model.</p> <p>Methods</p> <p>A discrete-event simulation model to evaluate demand and waiting time for cataract surgery was constructed. The model was reproduced and validated in five regions of Spain and was fed administrative data (population census, surgery rates, waiting list information) and data from research studies (incidence of cataract). The benefit of introducing a prioritization system was contrasted with the usual first-in, first-out (FIFO) discipline. The prioritization system included clinical, functional and social criteria. Priority scores ranged between 0 and 100, with greater values indicating higher priority. The measure of results was the waiting time weighted by the priority score of each patient who had passed through the waiting list. Benefit was calculated as the difference in time weighted by priority score between operating according to waiting time or to priority.</p> <p>Results</p> <p>The mean waiting time for patients undergoing surgery according to the FIFO discipline varied from 1.97 months (95% CI 1.85; 2.09) in the Basque Country to 10.02 months (95% CI 9.91; 10.12) in the Canary Islands. When the prioritization system was applied, the mean waiting time was reduced to a minimum of 0.73 months weighted by priority score (95% CI 0.68; 0.78) in the Basque Country and a maximum of 5.63 months (95% CI 5.57; 5.69) in the Canary Islands. The waiting time weighted by priority score saved by the prioritization system varied from 1.12 months (95% CI 1.07; 1.16) in Andalusia to 2.73 months (95% CI 2.67; 2.80) in Aragon.</p> <p>Conclusion</p> <p>The prioritization system reduced the impact of the variations found among the regions studied, thus improving equity. Prioritization allocates the available resources within each region more efficiently and reduces the waiting time of patients with greater need. Prioritization was more beneficial than allocating surgery by waiting time alone.</p

Dynamic Evolution of Pathogenicity Revealed by Sequencing and Comparative Genomics of 19 Pseudomonas syringae Isolates

Closely related pathogens may differ dramatically in host range, but the molecular, genetic, and evolutionary basis for these differences remains unclear. In many Gram- negative bacteria, including the phytopathogen Pseudomonas syringae, type III effectors (TTEs) are essential for pathogenicity, instrumental in structuring host range, and exhibit wide diversity between strains. To capture the dynamic nature of virulence gene repertoires across P. syringae, we screened 11 diverse strains for novel TTE families and coupled this nearly saturating screen with the sequencing and assembly of 14 phylogenetically diverse isolates from a broad collection of diseased host plants. TTE repertoires vary dramatically in size and content across all P. syringae clades; surprisingly few TTEs are conserved and present in all strains. Those that are likely provide basal requirements for pathogenicity. We demonstrate that functional divergence within one conserved locus, hopM1, leads to dramatic differences in pathogenicity, and we demonstrate that phylogenetics-informed mutagenesis can be used to identify functionally critical residues of TTEs. The dynamism of the TTE repertoire is mirrored by diversity in pathways affecting the synthesis of secreted phytotoxins, highlighting the likely role of both types of virulence factors in determination of host range. We used these 14 draft genome sequences, plus five additional genome sequences previously reported, to identify the core genome for P. syringae and we compared this core to that of two closely related non-pathogenic pseudomonad species. These data revealed the recent acquisition of a 1 Mb megaplasmid by a sub-clade of cucumber pathogens. This megaplasmid encodes a type IV secretion system and a diverse set of unknown proteins, which dramatically increases both the genomic content of these strains and the pan-genome of the species

"Feed from the Service": Corruption and Coercion in the State-University Relations in Central Eurasia

Education in Central Eurasia has become one of the industries, most affected by corruption. Corruption in academia, including bribery, extortions, embezzlement, nepotism, fraud, cheating, and plagiarism, is reflected in the region’s media and addressed in few scholarly works. This paper considers corruption in higher education as a product of interrelations between the government and academia. A substantial block of literature considers excessive corruption as an indicator of a weak state. In contrast to standard interpretations, this paper argues that in non-democratic societies corruption is used on a systematic basis as a mechanism of direct and indirect administrative control over higher education institutions. Informal approval of corrupt activities in exchange for loyalty and compliance with the regime may be used in the countries of Central Eurasia for the purposes of political indoctrination. This paper presents the concept of corruption and coercion in the state-university relations in Central Eurasia and outlines the model which incorporates this concept and the “feed from the service” approach. It presents implications of this model for the state-university relations and the national educational systems in Central Eurasia in general and offers some suggestions on curbing corruption

Eribulin-trastuzumab combination in HER2-positive metastatic breast cancer: updated results from a Russian observational study

Introduction. The standard of 1st line treatment of HER2+ metastatic breast cancer (mBC) is double blockade with trastuzumab and pertuzumab + taxane, 2nd line – Trastuzumab-emtazine. There are no standards for further treatment, as well as the optimal drug sequence. Expansion of the arsenal of therapeutic possibilities and the use of new combinations will certainly improve the results of treatment of this category of patients and increase their life expectancy.Aim. We sought to describe treatment patterns of  eribulin  and clinical outcomes of  metastatic HER2-positive breast cancer treated with eribulin  plus trastuzumab combination in  academic institutions and community oncology practices across the Russian Federation.Materials and methods. Patients treated with eribulin anytime between Jan, 2014 and Sep, 2019 with a diagnosis of MBC were identified by 23 providers from Russia. Providers retrospectively reviewed the health records and abstracted selected data points into an electronic case report form for each eligible patient.Results. 100 HER2-positive pts received eribulin in combination with trastuzumab. Median age was 55 (31–80) yrs and ECOG status 0–3. 67% pts had visceral metastases. Eribulin was administered as 1st and 2nd line to 23 (23%) pts, 3rd line to 31 (31%) pts, 4th line and later to 46 (46%). Median number of cycles was 5 (2–27). ORR was 12%, SD – 72%, SD &gt; 6 months – 23%, PD – 16%. Clinical efficacy rate achieved in 35%. Median PFS was 5.07 months (95% CI 4.021–6.119). According to the ER-status the response to eribulin and trastuzumab was different. ORR was 18.8%, SD 72.9% in pts with ER-positive MBC (n = 48) and 5.8% and 71.2% respectively in ER-negative MBC (n = 52). Median PFS was 6.97 months (95% CI 3.924–10.016) in pts with ER-positive MBC and 4.67 months (95% CI 3.841–5.499) in ER-negative MBC (р = 0.3). The combination was well tolerated: dose reductions were required in 12% pts, withdrawal due to toxicity in 4% pts. The most common type of toxicity was hematological with neutropenia Gr III-IV in 14 (14%) pts. Peripheral neuropathy Gr III was observed in 5 (5%) pts. No cardiotoxicity was detected.Conclusions. This is the real-life data of clinical outcomes for patients receiving eribulin plus trastuzumab for HER2-positive MBC throughout the Russian Federation. Our experience with eribulin plus trastuzumab demonstrates that this combination may be a potential effective treatment option for HER-2 positive MBC patients

СОБСТВЕННЫЙ ОПЫТ ПРИМЕНЕНИЯ ЭРИБУЛИНА В УСЛОВИЯХ РЕАЛЬНОЙ КЛИНИЧЕСКОЙ ПРАКТИКИ Г. МОСКВЫ И МОСКОВСКОЙ ОБЛАСТИ

Introduction. Eribulin, an non-taxane microtubule inhibitor, has been registered in Russia for patients with locally advanced or metastatic breast cancer (mBC) who received at least one chemotherapy regimen for a advanced disease, previous therapy should include anthracyclines and taxanes in adjuvant or metastatic setting, except the patients who could not be prescribed these drugs. We present our experience with eribulin in real clinical practice in Moscow and the Moscow Region.Patients and methods. We conducted a retrospective analysis of the experience with the use of eribulin in Moscow and the Moscow Region in 202 patients with mBC from January 2016 to February 2017 to assess the effectiveness and safety of the drug. All patients received previous therapy with anthracyclines and taxanes for locally advanced and / or metastatic cancer. The average age of patients at the time of inclusion in the analysis was 5 years (28–81). The status of the general condition on the ECOG 0-1 scale was registered in 81.3 % (100 / 123) of patients, the status of ECOG 2-3 in 18.7 % (23 / 123) of patients. The median of the number of courses of chemotherapy with eribulin is 4 (2–17). Patients received eribulin in 1-7 chemotherapy lines for metastatic disease. The average number of affected organs is 2 (1–5).Results. Complete response (CR) was in 3 (2 %) patients. Partial response (PR) was in 24 (15.7 %) patients, stabilization of the disease – in 89 (58. 2 %). Progression of the disease was recorded in 37 (24.1 %) patients. The median of progression-free survival (PFS) on the therapy was 4.64 (95 % CI 2.97-6.87) months. Stabilization of the disease for more than 6 months was registered in 28 (18.3 %) patients. The most significant toxicity was neutropenia and polyneuropathy (21 patients (10.4 %) and 7 patients (3.5 %), respectively).Dose reduction due to neutropenia was required by 26 patients (12.9 %). The objective response rate (ORR) depended on the chemotherapy line: in 1-3 lines the efficacy of the treatment was higher: the ORR was 21.6 %, compared to the 4th and subsequent lines – 12.3 %, respectively. With HER2-positive mBC, eribulin showed clinically significant results in combination with trastuzumab.Conclusions. Our analysis confirms that eribulin has a predictable and manageable safety profile, is an effective drug for the treatment of patients with different subtypes of mBC in a real clinical setting.Введение. Эрибулин – ингибитор динамики микротрубочек нетаксанового ряда, зарегистрирован в России для пациентов с местнораспространенным или метастатическим раком молочной железы (мРМЖ), получившим ранее не менее одного режима химиотерапии по поводу распространенного заболевания; предшествующая терапия должна включать антрациклины и таксаны в адъювантном режиме или в условиях метастатической формы заболевания, за исключением тех пациентов, которым не могли назначаться данные препараты. В настоящей работе представлен собственный опыт применения эрибулина в условиях реальной клинической практики г. Москвы и Московской области.Пациенты и методы. Проведен ретроспективный анализ опыта применения эрибулина в г. Москве и Московской области у 202 пациентов с мРМЖ с января 2016 по февраль 2017 г. для оценки эффективности и безопасности препарата. Все больные получили предшествующую терапию с использованием антрациклинов и таксанов по поводу местнораспространенного и / или метастатического рака. Средний возраст пациентов на момент включения в анализ составил 58 лет (28–81). Статус общего состояния по шкале ECOG 0–1 зарегистрирован у 81,3 % (100 / 123) больных, статус ЕCOG 2–3 – у 18,7 % (23 / 123) пациентов. Медиана числа проведенных курсов химиотерапии эрибулином – 4 (2–17). Пациенты получали эрибулин в 1–7 линиях химиотерапии по поводу метастатической формы заболевания. Среднее количество пораженных органов – 2 (1–5).Результаты. Полные регрессии (ПР) отмечены у 3 (2 %) больных, частичная регрессия (ЧР) – у 24 (15,7 %) пациентов, стабилизация заболевания – у 89 (58,2 %). Прогрессирование болезни зафиксировано у 37 (24,1 %) пациентов. Медиана выживаемости без прогрессирования (ВБП) на терапии эрибулином мРМЖ составила 4,64 мес. (95 % ДИ 2,97–6,87). Стабилизация заболевания более 6 мес. зарегистрирована у 28 (18,3 %) больных. Наиболее значимой токсичностью стали нейтропения и полинейропатия (21 (10,4 %) и 7 (3,5 %) пациентов соответственно). Редукция дозы эрибулина в связи с развитием нейтропении потребовалась 26 (12,9 %) больным.Частота объективного ответа (ЧОО) при терапии эрибулином зависела от линии химиотерапии: в 1–3 линиях эффективность лечения была выше – ЧОО составила 21,6 % по сравнению с 4-й и последующими линиями с ЧОО в 12,3 %. При HER2-положительном мРМЖ эрибулин продемонстрировал значительно лучшие результаты по ВБП в комбинации с трастузумабом по сравнению с монотерапией (медиана 4,64 мес. (95 % ДИ 2,94–6,6) и 2,58 мес. (95 % ДИ 2,15–3,6) соответственно).Выводы. Проведенный анализ подтверждает, что эрибулин, обладая предсказуемым и управляемым профилем безопасности, является эффективным препаратом для терапии пациентов с различными подтипами мРМЖ в условиях реальной клинической практики